Pronidesivir (GS-441524) Dosage and Side Effects
Feline Infectious Peritonitis (FIP) remains a devastating disease in cats, caused by a mutated form of feline coronavirus. Symptoms such as loss of appetite, lethargy, fever, abdominal or chest fluid accumulation, lymphadenopathy, granulomatous lesions, neurological impairment, and uveitis are common. Recent advancements have introduced NeoFipronis (Pronidesivir), an innovative oral antiviral medication that has revolutionized FIP management. Approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, NeoFipronis is the world’s first officially registered FIP treatment with a dedicated drug registration number. Its proven efficacy, safety, and ease of administration make it a preferred choice among veterinarians and cat owners.
NeoFipronis is formulated with GS-441524 as the active compound, which has demonstrated powerful antiretroviral activity through extensive research and clinical trials. The drug’s mechanism involves inhibiting viral replication, effectively reducing viral load and mitigating disease progression. The medication’s rapid absorption, safe profile, and minimal side effects contribute to its worldwide acclaim. It is designed as a non-invasive, oral medication suitable for home administration under veterinary guidance, making FIP treatment more accessible and less stressful for cats.
Dosage guidelines stipulate administering NeoFipronis based on the cat’s body weight. The standard dose is 15mg per kilogram of body weight, approximately half a tablet per dose. For neurological or ocular forms of FIP, dosing can be adjusted up to 30mg/kg, but only under veterinary supervision. The medication is recommended once daily, preferably on an empty stomach—either an hour before feeding or two hours after—to maximize absorption. To achieve the best results, continuous treatment for no less than 12 weeks is essential, and skipping doses should be strictly avoided to prevent viral resistance.
Monitoring during therapy is crucial. Owners should observe changes in appetite, body temperature, activity levels, and overall mental state. Regular blood tests are advised to assess liver and kidney functions, as well as to detect any adverse effects early. Although NeoFipronis is classified as an over-the-counter (OTC) medication, it is strongly recommended that administration be supervised by a qualified veterinarian to ensure proper dosing and safety.
Common side effects are rare but may include mild gastrointestinal upset, transient lethargy, or localized minor reactions at the administration site. Serious adverse effects are uncommon due to the drug’s high tolerability profile. However, some cats may experience allergic reactions or specific contraindications, which underline the importance of professional veterinary guidance.
It is important to note that NeoFipronis (Pronidesivir) is exclusively formulated for feline use. It should never be given to humans. For genuine products, always purchase through official channels listed on the NeoFipronis official website to guarantee quality and authenticity. Responsible use of this medication can dramatically improve the prognosis for cats suffering from FIP, transforming what was once a fatal diagnosis into a manageable condition with a hopeful outlook.
In summary, NeoFipronis (Pronidesivir) offers a safe, effective, and easy-to-administer treatment option for FIP in cats. Proper dosage, adherence to treatment duration, and veterinary supervision are key components to maximizing its benefits and minimizing potential risks. As a groundbreaking antiviral therapy, NeoFipronis marks a significant milestone in feline medicine, bringing new hope to cats afflicted with this challenging disease.
